Readiness of Specialists to Prescribe Humira Biosimilars: Cardinal Health Report Assesses the Field

By Gina Shaw

With 2023 poised to be the year of the adalimumab (Humira, AbbVie) biosimilar wave, Cardinal Health has issued a new report on market expansion and sustainability for biosimilars in the United States. The analysis includes the perspectives of more than 350 providers in the four specialties with the most potential for disruption in the coming year: rheumatology, gastroenterology, dermatology and ophthalmology. Most clinicians in all of these specialties reported familiarity and